Another batch of pharmaceutical companies passed the consistency evaluation!

 2021 marks the six years since the country officially launched the consistency evaluation of generic drugs
.
The data shows that in 2021, a total of 1,965 generic drugs of 573 companies have passed the consistency evaluation or are deemed to have passed the consistency evaluation, a year-on-year increase of more than 70%
.
Time enters 2022, and the consistency evaluation of generic drugs continues
.
It is reported that in the past week, many pharmaceutical companies have announced that their products have been reviewed
.
Luoxin Pharmaceutical’s subsidiary, meropenem for injection, passed the consistency evaluation of generic drugs.
Luoxin Pharmaceutical announced that Shandong Luoxin Pharmaceutical Group Co.
, Ltd.
Ropenem's "Drug Supplemental Application Approval Notice", the drug has passed the consistency evaluation of the quality and efficacy of generic drugs
.
Data show that meropenem is suitable for adults and children with infections caused by single or multiple meropenem-susceptible bacteria, and can be used alone or in combination with other antimicrobial agents to treat multiple infections
.
Xinhua Pharma's Amoxicillin Capsules Pass the Consistency Evaluation of Generic Drugs Xinhua Pharma issued an announcement.
Recently, Xinda Pharma, a wholly-owned subsidiary of the company, received the "Approval Notice for Supplementary Drug Application" for Amoxicillin Capsules approved and issued by the State Drug Administration.
, the product consistency evaluation application was approved
.
The data shows that amoxicillin is a penicillin antibiotic, which is effective against Streptococcus pneumoniae, Streptococcus hemolyticus and other Streptococcus species, Staphylococcus non-penicillinase, Enterococcus faecalis and other aerobic gram-positive cocci, Escherichia coli, Streptococcus mirabilis, etc.
Bacillus, Salmonella, Haemophilus influenzae, Neisseria gonorrhoeae and other non-β-lactamase-producing strains of aerobic Gram-negative bacteria and Helicobacter pylori have good antibacterial activity
.
Conba's Parecoxib Sodium for Injection passed the consistency evaluation of generic drugs Conba issued an announcement.
"Approval Notice for Supplementary Drug Application", the drug has passed the consistency evaluation of generic drugs
.
The data show that parecoxib sodium for injection is indicated for short-term treatment of postoperative pain.
It exerts anti-inflammatory and analgesic effects by specifically inhibiting COX-2 and blocking the synthesis of prostaglandins from arachidonic acid, and can reduce anesthesia.
Dosage of sexual analgesics
.
Tai Chi Group - Allergy Drug Consistency Evaluation Tai Chi Group announced that Southwest Pharmaceuticals, a subsidiary of the company, recently received the "Approval Notice for Supplementary Drug Application" from the State Food and Drug Administration, and its declared "Promethazine Hydrochloride Tablets" (dosage form) : tablet; specification: 12.
5mg; registration classification: chemical drug) passed the quality and efficacy consistency evaluation of generic drugs
.
The data show that the indications of promethazine hydrochloride tablets are: 1.
Skin and mucous membrane allergy: suitable for long-term, seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, urticaria, food allergy, skin scratching scar disease
.
2.
Motion sickness: prevent motion sickness, seasickness, and plane sickness
.
3.
Nausea and vomiting
.
Hanyu Pharmaceutical: Atosiban Acetate Injection passed the consistency evaluation of generic drugs Hanyu Pharmaceutical announced that the company's Atosiban Acetate Injection passed the consistency evaluation of the quality and efficacy of generic drugs
.
It is reported that this product was approved for the first time in China in December 2019
.
In 2020, this product has successively obtained marketing authorizations in Spain and Germany, becoming the first injection product of Hanyu Pharmaceutical to obtain marketing authorizations in EU countries
.
Zhendong Pharmaceutical Flunarizine Hydrochloride Capsules Passed the Consistency Evaluation of Generic Drugs Recently, Shanxi Zhendong Anxin Bio-Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of Shanxi Zhendong Pharmaceutical Co.
, Ltd.
, received the "Approval Notice for Supplementary Drug Application" issued by the State Drug Administration "(Notice No.
: 2021B04926), Flunarizine Hydrochloride Capsules have passed the quality and efficacy consistency evaluation of generic drugs
.
Flunarizine hydrochloride is a selective calcium antagonist, which can block excess calcium ions from transmembrane into cells, prevent excessive intracellular calcium load, and prevent a large amount of calcium from entering neurons during ischemia and hypoxia, improving brain microcirculation And neuron metabolism, inhibit cerebral vasospasm, platelet coagulation and blood viscosity increase, etc.
, in addition to cell membrane stabilization
.
This product is highly lipid-soluble and easily penetrates the blood-brain barrier
.
It can be used for the preventive treatment of typical (with aura) or atypical (without aura) migraine and the symptomatic treatment of vertigo caused by vestibular dysfunction
.
Shanghai Pharmaceutical's subsidiary Flunarizine Hydrochloride Capsules Review Shanghai Pharmaceuticals issued an announcement stating that the company's holding subsidiary Chia Tai Qingchunbao Pharmaceutical Co.
, Ltd.
received the "Drug Supplement Application" issued by the State Drug Administration for Flunarizine Hydrochloride Capsules Approval Notice" (Notice No.
: 2021B04925), the drug has passed the quality and efficacy consistency evaluation of generic drugs
.
Flunarizine hydrochloride capsules are mainly used for the preventive treatment of typical (with aura) or atypical (without aura) migraine, and the symptomatic treatment of vertigo caused by vestibular dysfunction
.